Bluebird’s Share Price Skyrocketing On Beta Thalassemia Optimism
This article was originally published in The Pink Sheet Daily
Executive Summary
On the strength of interim Phase I/II data presented at ASH and an investor presentation Dec. 10, bluebird bio is enjoying substantial growth in its stock price for the week.